Infectivity of blood components with low hepatitis B virus DNA levels identified in a lookback program

Transfusion

Volumn 47, Issue 7, 2007, Pages 1197-1205

  Satake, Masahiro ^a   Taira, Rikizo ^b   Yugi, Hisao ^b   Hino, Satoru ^b   Kanemitsu, Kimihiro ^b   Ikeda, Hisami ^b   Tadokoro, Kenji ^b  

^a Tokyo Red Cross Blood Center   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; VIRUS DNA;

ADULT; AGED; ANTIBODY TITER; ARTICLE; BLOOD BANK; BLOOD COMPONENT; BLOOD DONOR; BLOOD TRANSFUSION; CONTROLLED STUDY; DNA DETERMINATION; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INFECTION RISK; MALE; NUCLEIC ACID ANALYSIS; SCREENING TEST; SEROLOGY; VIRAL CONTAMINATION; VIRUS DETECTION; VIRUS INFECTIVITY; VIRUS TRANSMISSION;

BLOOD BANKS; BLOOD TRANSFUSION; DISEASE TRANSMISSION, HORIZONTAL; DNA, VIRAL; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; JAPAN; NUCLEIC ACID AMPLIFICATION TECHNIQUES; RED CROSS; RISK;

EID: 34250670322     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2007.01276.x     Document Type: Article

References (32)

1. Stramer SL, Glynn SA, Kleinman SH, et al. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N Engl J Med 2004 351 : 760 8.
2. Coste J, Reesink HW, Engelfriet CP, et al. Implementation of donor screening for infectious agents transmitted by blood by nucleic acid technology: update to 2003. Vox Sang 2005 88 : 289 303.
3. Mine H, Emura H, Miyamoto M, et al. High throughput screening of 16 million serologically negative blood donors for hepatitis B virus, hepatitis C virus and human immunodeficiency virus type-1 by nucleic acid amplification testing with specific and sensitive multiplex reagent in Japan. J Virol Methods 2003 112 : 145 51.
4. Tomono T, Murokawa H, Minegishi K, et al. Status of NAT screening for HCV, HIV and HBV: experience in Japan. Dev Biol (Basel) 2002 108 : 29 39.
5. Satake M. Infectious risks associated with the transfusion of blood components and pathogen inactivation in Japan. Int J Hematol 2004 80 : 306 10.
6. Busch MP, Glynn SA, Stramer SL, et al. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion 2005 45 : 254 64.
7. Staginnus U, Corash L. Economics of pathogen inactivation technology for platelet concentrates in Japan. Int J Hematol 2004 80 : 317 24.
8. Matsumoto C, Tadokoro K, Fujimura K, et al. Analysis of HBV infection after blood transfusion in Japan through investigation of a comprehensive donor specimen repository. Transfusion 2001 41 : 878 84.
9. Iizuka H, Ohmura K, Ishijima A, et al. Correlation between anti-HBc titers and HBV-DNA in blood units without detectable HBsAg. Vox Sang 1992 63 : 107 11.
10. Meng Q, Wong C, Rangachari A, et al. Automated multiplex assay system for simultaneous detection of hepatitis B virus DNA, hepatitis C virus RNA, and human immunodeficiency virus type 1 RNA. J Clin Microbiol 2001 39 : 2937 45.
11. Kuhns MC, Kleinman SH, McNamara AL, et al. Lack of correlation between HBsAg and HBV-DNA levels in blood donors who test positive for HBsAg and anti-HBc: implications for future HBV screening policy. Transfusion 2004 44 : 1332 9.
12. O'Riordan J, Williams P, Donnellan J. HCV and HIV-1 donor screening using nucleic acid amplification technique (NAT). Vox Sang 2005 89 : 266.
13. Katchaki JN, Siem TH, Brouwer R, Brandt KH, van der Waart M. Detection and significance of anti-HBc in the blood bank; preliminary results of a controlled prospective study. J Virol Methods 1980 2 : 119 25.
14. Allain JP, Hewitt PE, Tedder RS, Williamson LM. Evidence that anti-HBc but not HBV-DNA testing may prevent some HBV transmission by transfusion. Br J Haematol 1999 107 : 186 95.
15. Berninger M, Hammer M, Hoyer B, Gerin JL. An assay for the detection of the DNA genome of hepatitis B virus in serum. J Med Virol 1982 9 : 57 68.
16. Hsia CC, Purcell RH, Farshid M, et al. Quantification of hepatitis B virus genomes and infectivity in human serum samples. Transfusion 2006 46 : 1829 35.
17. Tanaka J, Kumagai J, Katayama K, et al. Sex- and age-specific carriers of hepatitis B and C viruses in Japan estimated by the prevalence in the 3,485,648 first-time blood donors during 1995-2000. Intervirology 2004 47 : 32 40.
18. Hu KQ. Occult hepatitis B virus infection and its clinical implications. J Viral Hepat 2002 9 : 243 57.
19. Preisler-Adams S, Schlayer HJ, Peters T, et al. Sequence analysis of hepatitis B virus DNA in immunologically negative infection. Arch Virol 1993 133 : 385 96.
20. Melegari M, Scaglioni PP, Wands JR. The small envelope protein is required for secretion of a naturally occurring hepatitis B virus mutant with pre-S1 deleted. J Virol 1997 71 : 5449 54.
21. Le Seyec J, Chouteau P, Cannie I, Guguen-Guillouzo C, Gripon P. Infection process of the hepatitis B virus depends on the presence of a defined sequence in the pre-S1 domain. J Virol 1999 73 : 2052 7.
22. Hui EK, Yi YS, Lo SJ. Hepatitis B viral core proteins with an N-terminal extension can assemble into core-like particles but cannot be enveloped. J Gen Virol 1999 80 : 2647 59.
23. Le Pogam S, Yuan TT, Sahu GK, Chatterjee S, Shih C. Low-level secretion of human hepatitis B virus virions caused by two independent, naturally occurring mutations (P5T and L60V) in the capsid protein. J Virol 2000 74 : 9099 105.
24. Li KS, Yamashiro T, Sumie A, et al. Hepatitis B virus harboring nucleotide deletions in the core promoter region and genotype B correlate with low viral replication activity in anti-HBe positive carriers. J Clin Virol 2001 23 : 97 106.
25. Michalak TI, Pasquinelli C, Guilhot S, Chisari FV. Hepatitis B virus persistence after recovery from acute viral hepatitis. J Clin Invest 1994 93 : 230 9.
26. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996 2 : 1104 8.
27. Blackberg J, Kidd-Ljunggren K. Occult hepatitis B virus after acute self-limited infection persisting for 30 years without sequence variation. J Hepatol 2000 33 : 992 7.
28. Yuki N, Nagaoka T, Yamashiro M, et al. Long-term histologic and virologic outcomes of acute self-limited hepatitis B. Hepatology 2003 37 : 1172 9.
29. Barker LF, Murray R. Relationship of virus dose to incubation time of clinical hepatitis and time of appearance of hepatitis-associated antigen. Am J Med Sci 1972 263 : 27 33.
30. Division of Blood Services of Japanese Red Cross Society. Transfusion-transmitted viral infection; 2004. Yuketsujouhou 2005 5 : 9.
31. Allain JP. Occult hepatitis B virus infection: implications in transfusion. Vox Sang 2004 86 : 83 91.
32. Inaba S, Ito A, Tadokoro K, et al. Individual nucleic amplification technology does not prevent all hepatitis B virus transmission by blood transfusion. Transfusion 2006 46 : 2028 9.